NFE2L2 and acute kidney injury: NRF2 activators, such as nitroalkane [37], CDDO-Im [38], bardoxolone methyl (CDDO-Me or RTA-402) [39], omaveloxolone (RTA-408) [40], and sildenafil [41], have been studied in AKI models, particularly during the acute stage of IRI [42].